Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo

This publication has 35 references indexed in Scilit:

• Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
  The Lancet, 2002
• Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lackingmdr1a-encoded P-glycoprotein
  Molecular Carcinogenesis, 2000
• Multidrug resistance (MDR) in cancer
  European Journal of Pharmaceutical Sciences, 2000
• Expression of P-Glycoprotein in Hepatocellular Carcinoma
  American Journal of Clinical Pathology, 2000
• BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
  Annual Review of Pharmacology and Toxicology, 1999
• Rising Incidence of Hepatocellular Carcinoma in the United States
  New England Journal of Medicine, 1999
• Expression of P‐glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation
  Journal of Gastroenterology and Hepatology, 1997
• Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product p-glycoprotein in primary liver carcinoma
  Cancer, 1994
• A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
  Hepatology, 1993
• Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial
  Cancer, 1988